These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

978 related articles for article (PubMed ID: 16024619)

  • 41. von Hippel-Lindau gene deletion detected in the stromal cell component of a cerebellar hemangioblastoma associated with von Hippel-Lindau disease.
    Vortmeyer AO; Gnarra JR; Emmert-Buck MR; Katz D; Linehan WM; Oldfield EH; Zhuang Z
    Hum Pathol; 1997 May; 28(5):540-3. PubMed ID: 9158701
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Up-regulation of hypoxia-inducible factor 2alpha in renal cell carcinoma associated with loss of Tsc-2 tumor suppressor gene.
    Liu MY; Poellinger L; Walker CL
    Cancer Res; 2003 May; 63(10):2675-80. PubMed ID: 12750296
    [TBL] [Abstract][Full Text] [Related]  

  • 43. GLUT1 immunoreaction patterns reliably distinguish hemangioblastoma from metastatic renal cell carcinoma.
    North PE; Mizeracki A; Mihm MC; Mrak RE
    Clin Neuropathol; 2000; 19(3):131-7. PubMed ID: 14606586
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Topotecan blocks hypoxia-inducible factor-1alpha and vascular endothelial growth factor expression induced by insulin-like growth factor-I in neuroblastoma cells.
    Beppu K; Nakamura K; Linehan WM; Rapisarda A; Thiele CJ
    Cancer Res; 2005 Jun; 65(11):4775-81. PubMed ID: 15930297
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Nuclear expression of hypoxia-inducible factor-1alpha in clear cell renal cell carcinoma is involved in tumor progression.
    Di Cristofano C; Minervini A; Menicagli M; Salinitri G; Bertacca G; Pefanis G; Masieri L; Lessi F; Collecchi P; Minervini R; Carini M; Bevilacqua G; Cavazzana A
    Am J Surg Pathol; 2007 Dec; 31(12):1875-81. PubMed ID: 18043042
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Renal cancer cells lacking hypoxia inducible factor (HIF)-1alpha expression maintain vascular endothelial growth factor expression through HIF-2alpha.
    Shinojima T; Oya M; Takayanagi A; Mizuno R; Shimizu N; Murai M
    Carcinogenesis; 2007 Mar; 28(3):529-36. PubMed ID: 16920734
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Propranolol reduces viability and induces apoptosis in hemangioblastoma cells from von Hippel-Lindau patients.
    Albiñana V; Villar Gómez de Las Heras K; Serrano-Heras G; Segura T; Perona-Moratalla AB; Mota-Pérez M; de Campos JM; Botella LM
    Orphanet J Rare Dis; 2015 Sep; 10():118. PubMed ID: 26394686
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Hypoxia inducible factor activates the transforming growth factor-alpha/epidermal growth factor receptor growth stimulatory pathway in VHL(-/-) renal cell carcinoma cells.
    Gunaratnam L; Morley M; Franovic A; de Paulsen N; Mekhail K; Parolin DA; Nakamura E; Lorimer IA; Lee S
    J Biol Chem; 2003 Nov; 278(45):44966-74. PubMed ID: 12944410
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Mutation of von Hippel-Lindau gene and expression of vascular endothelial growth factor in sporadic clear cell renal cell carcinoma and their relationships to angiogenesis].
    Zhang N; Gong K; Guo HF; Na X; Wu G; Yang XY; Xin DQ; Na YQ
    Zhonghua Yi Xue Za Zhi; 2004 Oct; 84(19):1620-4. PubMed ID: 15569457
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The von Hippel-Lindau tumor suppressor protein sensitizes renal cell carcinoma cells to tumor necrosis factor-induced cytotoxicity by suppressing the nuclear factor-kappaB-dependent antiapoptotic pathway.
    Qi H; Ohh M
    Cancer Res; 2003 Nov; 63(21):7076-80. PubMed ID: 14612498
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Specific oncolytic effect of a new hypoxia-inducible factor-dependent replicative adenovirus on von Hippel-Lindau-defective renal cell carcinomas.
    Cuevas Y; Hernández-Alcoceba R; Aragones J; Naranjo-Suárez S; Castellanos MC; Esteban MA; Martín-Puig S; Landazuri MO; del Peso L
    Cancer Res; 2003 Oct; 63(20):6877-84. PubMed ID: 14583486
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Transforming growth factor alpha is a target for the von Hippel-Lindau tumor suppressor.
    Knebelmann B; Ananth S; Cohen HT; Sukhatme VP
    Cancer Res; 1998 Jan; 58(2):226-31. PubMed ID: 9443397
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Vascular endothelial growth factor overexpression is correlated with von Hippel-Lindau tumor suppressor gene inactivation in patients with sporadic renal cell carcinoma.
    Igarashi H; Esumi M; Ishida H; Okada K
    Cancer; 2002 Jul; 95(1):47-53. PubMed ID: 12115316
    [TBL] [Abstract][Full Text] [Related]  

  • 54. In vitro and in vivo models analyzing von Hippel-Lindau disease-specific mutations.
    Rathmell WK; Hickey MM; Bezman NA; Chmielecki CA; Carraway NC; Simon MC
    Cancer Res; 2004 Dec; 64(23):8595-603. PubMed ID: 15574766
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Identification of novel VHL target genes and relationship to hypoxic response pathways.
    Maina EN; Morris MR; Zatyka M; Raval RR; Banks RE; Richards FM; Johnson CM; Maher ER
    Oncogene; 2005 Jun; 24(28):4549-58. PubMed ID: 15824735
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Mutations of the von Hippel-Lindau gene confer increased susceptibility to natural killer cells of clear-cell renal cell carcinoma.
    Perier A; Fregni G; Wittnebel S; Gad S; Allard M; Gervois N; Escudier B; Azzarone B; Caignard A
    Oncogene; 2011 Jun; 30(23):2622-32. PubMed ID: 21258414
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [The expression of hypoxia inducible factor-1,2 alpha in sporadic clear cell renal cell carcinoma and their relationships to the mutations of von Hippel-Lindau gene].
    Gong K; Zhang N; Na X; Wu G; Yang XY; Xin DQ; Na YQ
    Zhonghua Wai Ke Za Zhi; 2005 Mar; 43(6):390-3. PubMed ID: 15854350
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Extraneuraxial hemangioblastoma: A clinicopathologic study of 10 cases with molecular analysis of the VHL gene.
    Muscarella LA; Bisceglia M; Galliani CA; Zidar N; Ben-Dor DJ; Pasquinelli G; la Torre A; Sparaneo A; Fanburg-Smith JC; Lamovec J; Michal M; Bacchi CE
    Pathol Res Pract; 2018 Aug; 214(8):1156-1165. PubMed ID: 29941223
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Somatic von Hippel-Lindau disease gene mutation in clear-cell renal carcinomas associated with end-stage renal disease/acquired cystic disease of the kidney.
    Yoshida M; Yao M; Ishikawa I; Kishida T; Nagashima Y; Kondo K; Nakaigawa N; Hosaka M
    Genes Chromosomes Cancer; 2002 Dec; 35(4):359-64. PubMed ID: 12378530
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Regulation of the urokinase-type plasminogen activator system by the von Hippel-Lindau tumor suppressor gene.
    Los M; Zeamari S; Foekens JA; Gebbink MF; Voest EE
    Cancer Res; 1999 Sep; 59(17):4440-5. PubMed ID: 10485495
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 49.